Media coverage of Zogenix drug becoming more balanced, says Oppenheimer Oppenheimer believes that the media's coverage of Zogenix's Zohydro is becoming less negative. The firm thinks that this change could ease headline pressure on the stock. Oppenheimer keeps a $5 price target and Outperform rating on the shares.
News For ZGNX From The Last 14 Days
Check below for free stories on ZGNX the last two weeks.